Highlights Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-08 EDT			5-day change	1st Jan Change
5.135 ^USD	-0.68%		-2.19%	+9.26%

05-02	Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer	CI
04-10	Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	04-10	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051	03-14	CI
Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	03-11	CI
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	01-04	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Aprea Therapeutics, Inc. Announces Preclinical Data Supporting Highly Differentiated Wee1 Inhibitor, Atrn-1051, Reliable to Other Wee1 Inhibitors	23-09-11	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-30	AQ
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer	23-01-30	GL
Aprea Therapeutics, Inc. Announces CFO Changes	23-01-30	CI
Aprea Therapeutics, Inc. Doses First Patient in Phase 1/2A Clinical Trial of Oral ATN Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors	23-01-11	CI
APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-09	AQ
Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-12	AQ
APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-05-16	AQ
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Highlights

Filters